Quick Answer
NewAmsterdam Pharma Co N.V. reported Earnings Per Share Diluted of $1.72 (loss) per share for the year ending 2025.
- NewAmsterdam Pharma Co N.V. showed an increase of +32.8% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from NewAmsterdam Pharma Co N.V.'s annual report (Form 10-K), filed with the SEC on February 18, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $0.51 (loss) per share | Q2 2023: $0.47 (loss) per share | Q3 2023: $0.57 (loss) per share | Q1 2024: $1.06 (loss) per share | Q2 2024: $0.41 (loss) per share | Q3 2024: $0.18 (loss) per share | Q1 2025: $0.34 (loss) per share | Q2 2025: $0.15 (loss) per share | Q3 2025: $0.61 (loss) per share.
- Over the full 5 years of available data (2021 to 2025), NewAmsterdam Pharma Co N.V.'s Earnings Per Share Diluted has grown by 54.9%.
- Historical annual values: Fiscal year 2025: $1.72 (loss) per share | Fiscal year 2024: $2.56 (loss) per share | Fiscal year 2023: $2.15 (loss) per share | Fiscal year 2022: $1.19 (loss) per share | Fiscal year 2021: $3.81 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: